Multiple-center, randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: Effect on survival in patients with septic shock*

Crespo López, Ángel; A. Lorente, José; S. Steingrub, Jay; Bakker, Jan; McLuckie, Angela; M. Willatts, Sheila; Brockway, Michael; Anzueto, Antonio; Holzapfel, Laurent; P. Breen, Desmond; Silverman, Michael; Takala, Jukka; Donaldson, Jill; Arneson, Carl; Grove, G.Richard; H. Grossman, Steven; F. Grover, Robert

doi:10.1097/01.ccm.0000105581.01815.c6

Public

Multiple-center, randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: Effect on survival in patients with septic shock*

Published in Critical Care Medicine • Jan 1, 2004

Authors:

Ángel Crespo López

José A. Lorente

Jay S. Steingrub

Abstract

OBJECTIVE: To assess the safety and efficacy of the nitric oxide synthase inhibitor 546C88 in patients with septic shock. The predefined primary efficacy objective was survival at day 28. DESIGN: Multiple-center, randomized, two-stage, double-blind, placebo-controlled, safety and efficacy study. SET...

Subject

Medicine

Septic shock

Placebo

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!